Merlino C, Giacchino F, Tognarelli G, Cavallo R, Re D, Sinesi F, Segoloni G, Negro Ponzi A
Istituto di Microbiologia, Università degli Studi, Torino.
Minerva Urol Nefrol. 1996 Sep;48(3):139-43.
We have studied EBV infection in renal transplant patients during the first year after transplantation. At trasplantation all patients were EBV seropositive and reactivation of EBV infection was demonstrated in 54% cases after one year. CMV active infection was also demonstrated in 42% of patients with EBV reactivation. No correlation was observed between EBV reactivation and age, sex, immunosuppressive treatment, degree of immunosuppression or donor/recipient HLA matching. A correlation between immunosuppressive treatment, EBV infection and lymphoproliferative disorders (LD) is described in literature, however none of our patients developed LD so far, probably due to the different immunosuppressive protocol employed.
我们研究了肾移植患者移植后第一年的EB病毒(EBV)感染情况。移植时所有患者EBV血清学均为阳性,一年后54%的病例出现EBV感染再激活。在42%EBV再激活的患者中也证实有巨细胞病毒(CMV)活动性感染。未观察到EBV再激活与年龄、性别、免疫抑制治疗、免疫抑制程度或供体/受体人类白细胞抗原(HLA)配型之间存在相关性。文献中描述了免疫抑制治疗、EBV感染与淋巴增殖性疾病(LD)之间的相关性,然而我们的患者目前均未发生LD,这可能是由于采用了不同的免疫抑制方案。